RNAi for the Treatment of People with Hemophilia: Current Evidence and Patient Selection
Authors:
Open Access
- 1 April 2023
- journal article
- review article
- Published by Taylor & Francis in Journal of Blood Medicine
- Vol. ume 14, 317-327
Abstract
Severe hemophilia is associated with spontaneous, prolonged and recurrent bleeding. Inadequate prevention and treatment of bleeding can lead to serious morbidity and mortality. Due to the limitations of intravenous clotting factor replacement, including the risk of inhibitory antibodies, innovative novel therapies have been developed that have dramatically changed the landscape of hemophilia therapy. Ribonucleic acid interference (RNAi) has brought the opportunity for multiple strategies to manipulate the hemostatic system and ameliorate the bleeding phenotype in severe bleeding disorders. Fitusiran is a RNAi therapeutic that inhibits the expression of the natural anticoagulant serpin antithrombin. Reduction in antithrombin is known to cause thrombosis if coagulation parameters are otherwise normal and can rebalance hemostasis in severe hemophilia. Reports from late stage clinical trials of fitusiran in hemophilia A and B participants, with and without inhibitory antibodies to exogenous clotting factor, have demonstrated efficacy in preventing bleeding events showing promise for a future “universal” prophylactic treatment of individuals with moderate-severe hemophilia.Keywords
This publication has 76 references indexed in Scilit:
- Modulation of Mouse Coagulation Gene Transcription following Acute In Vivo Delivery of Synthetic Small Interfering RNAs Targeting HNF4α and C/EBPαPLOS ONE, 2012
- Heparin Cofactor II: Discovery, Properties, and Role in Controlling Vascular HomeostasisSeminars in Thrombosis and Hemostasis, 2011
- Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relativesBlood, 2009
- Interpatient Phenotypic Inconsistency in Severe Congenital Hemophilia: A Systematic Review of the Role of Inherited ThrombophiliaSeminars in Thrombosis and Hemostasis, 2009
- Knocking down barriers: advances in siRNA deliveryNature Reviews Drug Discovery, 2009
- Protein S deficiency: a clinical perspectiveHaemophilia, 2008
- Sequence- and target-independent angiogenesis suppression by siRNA via TLR3Nature, 2008
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaNew England Journal of Medicine, 2007
- Heparin Cofactor II Modulates the Response to Vascular InjuryArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and BThrombosis and Haemostasis, 2005